SCHEMBL3394794

SCHEMBL3394794

CCCCCCCCC(O)C(O)(CO)CCCCCCCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
CYP2D6 P10635 2/20 0.40
SPHK1 Q9NYA1 2/20 0.40
GMNN O75496 1/20 0.40
POLB P06746 1/20 0.40
THPO P40225 1/20 0.40
MTOR P42345 1/20 0.40
BLM P54132 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
CETP P11597 1/20 0.40
HTT P42858 1/20 0.40
UBE2N P61088 1/20 0.40
GPR84 Q9NQS5 3/20 0.38
FFAR1 O14842 1/20 0.38
FDPS P14324 9/20 0.38
GGPS1 O95749 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9545095 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1147732 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL27358898 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL27645826 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL8682114 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL9137980 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1147850 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL4875812 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1147869 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL15016341 1.00 LMNA (0.42) LMNACYP2D6SPHK1GMNNPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716558-B2 Method of altering glycosylation of proteins in response to nojirimycin glucuronide in a plant cell expressing glucuronidase MARKER GENE TECHNOLOGIES, INC. (US) 2014-05-06 US disclosed
EP-1600449-B1 Process for producing an ester, acetal, ketal, ether or alkyl glycoside KAO CORP (JP) 2010-12-29 EP disclosed
US-20060105915-A1 Compositions and methods for targeted enzymatic release of cell regulatory compounds MARKER GENE TECHNOLOGIES, INC. 2006-05-18 US disclosed
EP-1600449-A1 Process for producing an ester, acetal, ketal, ether or alkyl glycoside Kao Corporation (JP) 2005-11-30 EP disclosed
EP-0980869-B1 ALUMINUM COMPOUNDS AND USE THEREOF KAO CORP (JP) 2005-06-08 EP disclosed
US-20040101932-A1 Compositions and methods for targeted enzymatic release of cell regulatory compounds MARKER GENE TECHNOLOGIES, INC. 2004-05-27 US disclosed
US-6656917-B1 Enzyme encoded by vector recognizes and binds to the inactive conjugate, and releases the bioactive compound from conjugation in an amount effective to enhance growth MARKER GENE TECHNOLOGIES, INC. 2003-12-02 US disclosed
US-6207845-B1 ORGANOALUMINUM COMPOUND; ACID CATALYST KAO CORPORATION (JP) 2001-03-27 US disclosed
EP-0980869-A1 ALUMINUM COMPOUNDS AND USE THEREOF Kao Corporation (JP) 2000-02-23 EP disclosed
US-5439944-A Red blood cell substitute emulsions containing alkyl- or alkylglyucerophosphoryl choline surfactants and methods of use HEMAGEN/PFC (US) 1995-08-08 US disclosed
US-5439669-A Stable physiologically acceptable emulsion of fluorochemical, water, surfactant HEMAGEN/PFC (US) 1995-08-08 US disclosed
EP-0663829-A1 EMULSIONS CONTAINING ALKYL- OR ALKYLGYLCEROPHOSPHORYL CHOLINE SURFACTANTS AND METHODS OF USE HEMAGEN/PFC (US) 1995-07-26 EP disclosed
US-5304325-A Emulsions of fluorochemical, water, surfactant; synthetic blood HEMAGEN/PFC (US) 1994-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040101932-A1 Compositions and methods for targeted enzymatic release of cell regulatory compounds GUSB, PREP, PEPD LMNA 1080/4885CYP2D6 87/4885SPHK1 3857/4885
US-20060105915-A1 Compositions and methods for targeted enzymatic release of cell regulatory compounds GUSB, PREP, PEPD LMNA 1080/4885CYP2D6 87/4885SPHK1 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.